Butterfly Network, Inc.
BFLY-WT
New York Stock Exchange0.04
USD
+0.00
- -
CIK
0001804176
ISIN
US1241551100
CUSIP
124155110
Return %
Stock
S&P500
1Y
-92.31
26.53
3Y
-87.13
76.60
5Y
-92.79
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Joseph M. DeVivo
- Full Time Employees
- 225
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 530 Old Whitfield Street Burlington DE United States of America
- IPO Date
- Jul 13, 2020
- CIK
- 0001804176
- Website
- butterflynetwork.com
- Similar Companies
- Business
- Butterfly Network, Inc. develops, manufactures and commercializes digital ultrasound imaging solutions leveraging proprietary Ultrasound-on-Chip technology for point-of-care applications worldwide; core products include the whole-body handheld Butterfly iQ3 probe, predecessor iQ+ system, Compass enterprise workflow software, AI-powered tools such as Auto B-line Counter and gestational age assessment, Butterfly Cloud for image storage and collaboration, and subscription-based services encompassing tele-guidance, educational resources and EMR integration; the company targets clinicians, health systems, medical education institutions, emergency services and veterinary professionals with portable, AI-enhanced devices and platforms that connect to mobile devices for assessment, diagnosis and treatment. Founded in 2011 and headquartered in Burlington, Massachusetts, Butterfly Network operates primarily in the United States with international distribution through direct sales, partners and e-commerce, serving over 145,000 customers and more than 130 enterprise software accounts. Recent developments encompass the 2023 launch of the iQ3 probe with enhanced processing, a major enterprise-wide deployment in 2025 across a top-five global health system, partnerships including generative AI collaborations for imaging innovation and integrations with iCardio, HeartFocus and DeepEcho for FDA-cleared clinical tools, expansion into home care and Octave business lines with projected state-level deployments for congestive heart failure management, introduction of Compass AI for workflow automation and compliance, achievement of international security certifications, revised 2025 revenue guidance to $91-$95 million reflecting 9% Q2 growth, and a licensing agreement with Midjourney for ultrasound technology amid 35% Q4 2024 revenue increase and enterprise recurring revenue growth.